Komipharm International Co. Ltd
Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis se… Read more
Komipharm International Co. Ltd - Asset Resilience Ratio
Komipharm International Co. Ltd (041960) has an Asset Resilience Ratio of 2.23% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Komipharm International Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Komipharm International Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩2.98 Billion | 2.23% |
| Total Liquid Assets | ₩2.98 Billion | 2.23% |
Asset Resilience Insights
- Limited Liquidity: Komipharm International Co. Ltd maintains only 2.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Komipharm International Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Komipharm International Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620 |
Pharmaceuticals | 4.28% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Sam-A Pharm. Co. Ltd
KQ:009300 |
Pharmaceuticals | 34.37% |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040 |
Pharmaceuticals | 5.22% |
|
WooGene B&G Co. Ltd
KQ:018620 |
Pharmaceuticals | 3.35% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
|
EstechPharma Co. Ltd
KQ:041910 |
Pharmaceuticals | 9.64% |
Annual Asset Resilience Ratio for Komipharm International Co. Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Komipharm International Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 8.15% | ₩10.00 Billion | ₩122.77 Billion | +8.15pp |
| 2023-12-31 | 0.00% | ₩-340.00 | ₩118.60 Billion | -9.67pp |
| 2022-12-31 | 9.67% | ₩10.80 Billion | ₩111.75 Billion | -2.42pp |
| 2021-12-31 | 12.08% | ₩13.93 Billion | ₩115.26 Billion | -1.95pp |
| 2020-12-31 | 14.03% | ₩17.10 Billion | ₩121.91 Billion | -2.62pp |
| 2019-12-31 | 16.65% | ₩20.92 Billion | ₩125.64 Billion | +0.80pp |
| 2018-12-31 | 15.85% | ₩22.18 Billion | ₩139.90 Billion | -2.62pp |
| 2017-12-31 | 18.48% | ₩27.58 Billion | ₩149.27 Billion | -0.12pp |
| 2016-12-31 | 18.59% | ₩27.86 Billion | ₩149.84 Billion | +18.33pp |
| 2015-12-31 | 0.26% | ₩350.00 Million | ₩133.39 Billion | -7.78pp |
| 2014-12-31 | 8.05% | ₩10.01 Billion | ₩124.40 Billion | +8.03pp |
| 2013-12-31 | 0.02% | ₩17.07 Million | ₩108.80 Billion | -0.07pp |
| 2011-12-31 | 0.09% | ₩55.36 Million | ₩64.12 Billion | -- |